A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Collaborators: Gilead Sciences